# Alivus Life Sciences share price today (Alivus Life Sciences Ltd, NSE: ALIVUS) > Alivus Life Sciences share price today: ₹1,436.90 at the NSE close on 20 November 2026, up 59.0% in a year. Alivus Life Sciences (NSE: ALIVUS) is worth ₹17,665 crore, trades at a P/E of 26.3 and has closed between ₹880.15 and ₹1,558.70 over the past 52 weeks. > Alivus Life Sciences Ltd's share price has risen faster than its earnings: +59.0% in a year, against +16.0% for earnings per share. ALIVUS · Pharmaceuticals Bulk Drugs & Formulation · data as of 20 November 2026. Page: https://www.sectoralpha.in/stocks/alivus-life-sciences-ltd Our full read on Alivus Life Sciences, including whether management kept its promises and what could stop it, is in the Sector Alpha newsletter: https://newsletter.sectoralpha.in/p/deep-dive-why-alivus-is-beating-the?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms ## Key numbers - Business trend: Getting better, from the last 12 quarters - Price: ₹1,436.90 (+59.0% in a year) - P/E: 26.3× (higher than 81% of the last 5.3 years) - Revenue (Sep 2026): ₹682 Cr (+16.0% on a year ago) - Profit (Sep 2026): ₹197 Cr (+51.5% on a year ago) - Operating margin: 38.9% (+8.5 points on a year ago) - ROCE: 24%, FY26 - ROIC: 24.0%, against a 12.0% cost of capital: +12.0 points The main question: the share price moved +59.0% in a year while yearly earnings per share moved +16.0%. The difference came from the market paying a higher multiple. ## What is the Alivus Life Sciences share price today? Alivus Life Sciences Ltd's share price was ₹1,436.90 at the close on 20 November 2026. It has been rising for 31 weeks. That is 19.0% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹880 and ₹1,559, and at that close it sat 82% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 26 weeks in a row. Over the last 5.3 years the share price moved +92% while the NIFTY 500 moved +70%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Alivus Life Sciences this quarter? Three changes stood out: best operating margin in 16 quarters, revenue up on a year earlier for 8 quarters in a row and profit up on a year earlier for 8 quarters in a row. 1. Best operating margin in 16 quarters Operating margin was 39% in the September 2026 quarter, against 30% a year earlier. 2. Revenue up on a year earlier for 8 quarters in a row In the September 2026 quarter revenue was ₹682 crore, +16% on a year earlier. Why: Revenue rose because the business outside GPL grew 20.8%, helped by new product launches and demand across Europe, Japan, North America and other markets. Next results: check whether GPL volume picks up in the second half as management expects. From the earnings call on 30 Oct 2026. 3. Profit up on a year earlier for 8 quarters in a row In the September 2026 quarter profit was ₹197 crore, +51.5% on a year earlier. ## What are Alivus Life Sciences' latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Alivus Life Sciences reported revenue of ₹682 crore, up 16.0% from ₹588 crore a year earlier, and a profit of ₹197 crore, up 51.5% from ₹130 crore. ### Alivus Life Sciences results: July to September 2026 against a year earlier | Measure | July to September 2026 | July to September 2025 | Change | | --- | --- | --- | --- | | Revenue | ₹682 crore | ₹588 crore | +16.0% | | Profit | ₹197 crore | ₹130 crore | +51.5% | | Earnings per share | ₹16.03 | ₹10.60 | +51.2% | | Operating margin | 38.9% | 30.4% | +8.5 points | The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Alivus Life Sciences' management discussed these results on a call held on 30 October 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.) ## What is the Alivus Life Sciences share price history? Alivus Life Sciences closed at ₹1,436.90 on 20 November 2026, up 59.0% from ₹903.85 a year earlier (21 November 2025) and up 129.5% over five years. Its highest weekly close since August 2021 was ₹1,558.70 on 8 November 2026. ### Alivus Life Sciences share price: then and now | When | Close | Change to 20 Nov 2026 | | --- | --- | --- | | 1 week ago · 13 Nov 2026 | ₹1,460.60 | −1.6% | | 1 month ago · 19 Oct 2026 | ₹1,268.60 | +13.3% | | 6 months ago · 22 May 2026 | ₹1,039.00 | +38.3% | | 1 year ago · 21 Nov 2025 | ₹903.85 | +59.0% | | 3 years ago · 17 Nov 2023 | ₹626.35 | +129.4% | | 5 years ago · 18 Nov 2021 | ₹626.05 | +129.5% | | Earliest weekly close in our records · 6 Aug 2021 | ₹748.50 | +92.0% | | Highest weekly close since August 2021, also the 52-week high · 8 Nov 2026 | ₹1,558.70 | −7.8% | | Lowest weekly close since August 2021 · 3 Feb 2023 | ₹376.30 | +281.8% | | 52-week low (weekly close) · 9 Jan 2026 | ₹880.15 | +63.3% | Weekly closing prices. Each change is the move from that price to the 20 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (285 weekly closes from 6 August 2021 to 20 November 2026.) ## What is the latest news on Alivus Life Sciences? 20 Nov 2026: Alivus Life Sciences closed at ₹1,436.90, down 1.6% on the week and up 13.3% on the month. 30 Oct 2026: Alivus Life Sciences held its results call for July to September 2026. Management guided: FY27 revenue growth 10-12% reiterated on H2 strength and launch traction. ### Earlier - Results for July to September 2026: Revenue up 16.0% and profit up 51.5% on a year earlier. - 1 Sep 2026: ex-date for a dividend of ₹5 a share. ## What dividend does Alivus Life Sciences pay? Alivus Life Sciences paid ₹5 a share in regular dividends in the 12 months to 20 November 2026 (1 payment), a yield of 0.35% at the ₹1,436.90 close on 20 November 2026. The last was a dividend of ₹5 a share, ex-date 1 September 2026. ### Alivus Life Sciences dividends since 1 April 2021 | Ex-date | Dividend per share | Type | Record date | | --- | --- | --- | --- | | 1 Sep 2026 | ₹5 | Dividend | same day | | 1 Sep 2025 | ₹5 | Dividend | same day | | 17 Oct 2023 | ₹22.50 | Interim | same day | | 24 Mar 2023 | ₹21 | Interim | same day | | 15 Sep 2022 | ₹10.50 | Dividend | n/a | | 22 Nov 2021 | ₹10.50 | Interim | 23 Nov 2021 | Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 4 of 5 Of the last 5 financial years, years with an NSE dividend record Yes. Alivus Life Sciences Ltd paid out 11% of its profit as dividends in FY26, and it paid a dividend in 5 of its last 9 reported years. (From the NSE corporate-actions record, read 20 November 2026.) ## What did Alivus Life Sciences management say on the latest results call? On the call for July to September 2026, held on 30 October 2026, Alivus Life Sciences' management guided: FY27 revenue growth 10-12% reiterated on H2 strength and launch traction. > “Accordingly, we reiterate our FY27 revenue growth guidance of 10% to 12%. We are confident of delivering EBITDA margins in the 35% to 36% range in FY27.” > Yasir Rawji, on the call for July to September 2026 ### What management guided - FY27 operating margin 35-36% guided despite H2 mix dilution from GPL pickup. - FY28 operating profit aiming similar to FY27 with 30-32% floor if conditions weaken. - Solapur Phase 1 operational in October to December 2026 as intermediate and backward-integration site progressing as planned. - CDMO to double in 3-4 years to 12-15% of revenue with at least one new project in H1 next year. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/43629-30-Oct-2026.pdf). (From the call for July to September 2026, 30 October 2026.) ## What to watch in Alivus Life Sciences' next results? When Alivus Life Sciences reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Solapur Phase 1 commissioning against flagged quarter - check operational status, first batches and inspection triggers. Management raised each of these on the latest results call. - Solapur Phase 1 commissioning against flagged quarter - check operational status, first batches and inspection triggers. - GPL volume rebound in H2 and margin within guided band - check pickup pace against dilution commentary. - CDMO quarterly cadence given lumpiness warning - check annual improvement and new-project closure progress versus volatility. ## Which stock lists is Alivus Life Sciences on? Alivus Life Sciences is on 4 of our India lists: Multibagger study list, Momentum stocks, Small & mid cap stocks and Pharma stocks. - [Multibagger study list Study stage: late](https://www.sectoralpha.in/multibagger-stocks-india) - [Momentum stocks Market value: ₹17,829 crore](https://www.sectoralpha.in/momentum-stocks-india) - [Small & mid cap stocks Size rank in India: 393](https://www.sectoralpha.in/small-cap-stocks-india) - [Pharma stocks Market value: ₹17,829 crore](https://www.sectoralpha.in/sectors/pharma-stocks-india) ## Is Alivus Life Sciences profitable? Alivus Life Sciences Ltd earned ₹197 Cr of net profit in the Sep 2026 quarter, +51.5% on the same quarter a year earlier. That is the 8th quarter in a row of profit growth. Full-year FY26 profit was ₹564 Cr. The Sep 2026 quarter's profit is 28.9% of that quarter's revenue. The same quarter a year earlier earned ₹130 Cr. For the full year, FY26 profit was ₹564 Cr (+16.0% on the year before). Why profit moved: revenue changed +16.0% on a year earlier and the margin moved +8.5 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +26.7% and revenue +8.3%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Alivus Life Sciences make, and is it growing? Alivus Life Sciences Ltd reported ₹682 Cr of revenue in the Sep 2026 quarter, +16.0% on the same quarter a year earlier. That is the 8th quarter in a row with growth on the year before. The last full year, FY26, came in at ₹2,552 Cr. The last four reported quarters add to ₹2,684 Cr. Why this happened. The CDMO versus branded formulations divergence favours a larger CDMO mix if projects convert. Management cites existing projects, new inquiries and planned contracts, while declining to attach a firm revenue forecast. That makes conversion evidence more important than the size of the stated funnel. A growth rate over several years is not shown, because there are too few years of figures to work one out properly. FY26 revenue was ₹2,552 Cr, +6.9% on the year before. Is growth speeding up? Revenue over the last 12 months grew +8.1%, against +10.3% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +26.2%, against +25.9% a year (stabilising). ## How much of every ₹100 of sales does Alivus Life Sciences keep? Alivus Life Sciences Ltd's operating margin was 38.9% in the Sep 2026 quarter, 8.5 percentage points higher than the same quarter a year ago. Across 9 years it has been between −4.0% and 31.4%. The latest quarter is above every full year in that period. Why this happened. The generic-to-specialty value migration is visible in the latest call: management attributes non-GPL growth to launches and demand across markets. This is the primary operating offset while GPL customers reduce inventory. Why the margin moved: operating margin changed +8.4 percentage points on the year while gross margin changed +6.7 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Alivus Life Sciences' profit turning into cash? Over the last 3 years, 90% of Alivus Life Sciences Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹565 Cr of operating cash against ₹564 Cr of profit. After ₹307 Cr of spending on assets, ₹258 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 90% of profit came in as cash: the cash cycle got 26 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 3.2× depreciation over three years. The next section checks what that spending is building. ## Where does Alivus Life Sciences' cash go? Alivus Life Sciences Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 267 days in FY26, up from 241 days in FY21. It spent ₹602 Cr on assets over the last 3 years. Customers take 153 days to pay, and stock sits for 246 days on average. At FY26 sales of ₹2,552 Cr, each day of that cycle ties up about ₹7.0 Cr, so roughly ₹1,867 Cr is tied up in the business at any time. FY26: customers took 153 days to pay and stock sat for 246 days, about 8.1 months of sales sitting as stock, for a full cycle of 267 days, longer than FY21's 241. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 246 days. Customers pay about 153 days after that. Suppliers are paid at 132 days. Together that makes the 267-day cycle. Spending on assets: ₹602 Cr over the last 3 years, against ₹189 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹284 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Alivus Life Sciences' P/E ratio, and how does it compare with its own history? Alivus Life Sciences Ltd's P/E is 26.3×, near the high end of its own history: higher than 81% of past readings. Its usual P/E (the middle reading) is 21.2×, over 5.3 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹54.57. Why the multiple is where it is: over the past year earnings per share moved +16.0% while the price moved +59.0%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +18.1% a year; about +14.3% a year came from earnings growth and about +3.8 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Alivus Life Sciences business getting better or worse? Alivus Life Sciences Ltd's business is getting better. Profit growth was −15.0% 7 quarters ago and has recovered to +26.2%, with ROCE steady at 25.8% (four quarters to Sep 2026). This is based on 12 quarters of 4 measures. Why it matters: a lasting rise from a low is what this page is built to show. ## What is the Alivus Life Sciences story, and has it been checked? Alivus Life Sciences Ltd's story is not scored yet against the checks our research set on 22 August 2026. Where it sits in its own cycle: mid expansion. Still open: The thesis breaks if non-GPL growth no longer offsets GPL weakness while operating margin falls below management's stated range and the promised capacity and CDMO milestones slip again. Our read, 22 August 2026. From the numbers. From the price. Price stage 2, week 31, above its 200-day line, relative strength falling. Where they disagree. What is not proven yet. The thesis breaks if non-GPL growth no longer offsets GPL weakness while operating margin falls below management's stated range and the promised capacity and CDMO milestones slip again. The test written in advance. The test written in advance. CDMO contract timing. Measured by: CDMO contract timing Confirmation of the planned new contracts and disclosed CDMO mix in the next result. by the next result. What the company does. The latest quarter delivered revenue growth and profit growth, with operating margin above the prior-year level as launches, mix and efficiency offset GPL weakness. What the surface reading misses. The surface reading is: Profit growth above revenue growth indicates operating leverage. The research reads it further: The gap is consistent with higher operating margin and management's stated mix and efficiency bridge, not a one-quarter exceptional-item flag in the supplied ledger. What the surface reading misses. The surface reading is: Margin expansion implies improving economics. The research reads it further: The latest margin is above the mid-cycle margin and management attributes the improvement to mix, launches and efficiency; this supports execution but means current earnings are not trough-depressed. Lever 2 · Value-added mix: building. Non-GPL growth is offsetting GPL inventory rationalization and broadening the revenue base. What proves it keeps working: Non-GPL launch engine. It stops working if New launches fail to scale or GPL weakness persists without enough non-GPL growth to cover it. Lever 1 · Operating leverage: building. Launch mix and operating efficiency have lifted margins above the previous-year quarter. What proves it keeps working: Mix and process margin bridge. It stops working if Raw-material inflation exceeds pass-through and GPL mix normalizes faster than launch economics scale. Lever 7 · Consolidation: building. Returning programmes and prospective contracts can add higher-value revenue, but the funnel remains timing-sensitive. What proves it keeps working: CDMO funnel conversion. It stops working if The planned contracts slip again or existing programmes do not improve in the second half. Lever 6 · Order-book wins: building. The planned sites can add regulated-market capacity and lower precursor cost after commissioning. What proves it keeps working: Capacity and backward integration. It stops working if Commissioning or regulatory inspection slips further, or utilisation remains below the expected ramp. Sources: our stock research file (22 August 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes. ## Did Alivus Life Sciences management deliver what it promised? What Alivus Life Sciences Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met. FY27 EBITDA Margin Guidance Raised Without Reconciliation · 30 October 2026. In Jul 2026 and May 2026, management guided to FY27 EBITDA margins of 30% to 32%, while the Oct 2026 call raised the range to 35% to 36%. Although the latest call cited better revenue mix and operating efficiencies, it did not quantify or reconcile why the prior full-year framework was superseded, creating a material change for earnings estimates. CDMO Contract Commitments Shifted · 30 October 2026. The May 2026 and Jul 2026 calls pointed to two new CDMO deals in the early part of H2 FY27, with the Jul 2026 discussion still framing the contracts as expected and on track. By Oct 2026, management had reframed the expected closure as the first half of next year and reduced the firm commitment to at least one project, representing a material timing and scope change without an explanation for the slippage. CDMO Capacity Narrative Reversed · 30 October 2026. In Jul 2026, management broadly said capacity was not a challenge for Alivus and described its facilities as top of the line. In Oct 2026, it acknowledged that the company had not entertained large-volume CDMO opportunities because it lacked capacity, changing the assessment of CDMO growth headroom and requiring clarification of the scope of the earlier statement. New-Launch Margin Durability Changed · 30 October 2026. Jul 2026 presented the margin benefit from launches as stable and continuing, whereas Oct 2026 said margins on newly launched products have an 18-24-month shelf life before normalizing. Every quote above is taken word for word from the company’s own earnings calls. ## What is Alivus Life Sciences management's track record? The company keeps internal funding as its stated plan despite delayed spending; that remains a forecast. Prior stress-call summaries carry date mismatches, so they cannot establish a dated delivery record. Streams 1-2 REVEAL the named patent restriction and current GST demand; no material-size misconduct finding is established. Stream 5 returned no matching excerpts. ### Regulatory and governance record Incyte and Vertex patent disputes, the GST demand and the older fire-related pollution notice are named and retained. The excerpts show no proven fraud, lie or adverse misconduct ruling, and do not establish an open case of real financial size under the current verdict bar. The underlying GST grounds and patent exposure remain gaps. Sources: - [alivus.b-cdn.net](https://alivus.b-cdn.net/alivus_pdfs/investors/financials/reports_presentation/Alivus%20Life%20Sciences%20Limited_AR_2026.pdf) - [indiankanoon.org](https://indiankanoon.org/doc/89368610) - [tijorifinance.com](https://tijorifinance.com/company/glenmark-life-sciences-ltd/shareholding) (Checked 14 October 2026.) ## How much does Alivus Life Sciences earn on its capital? Alivus Life Sciences Ltd earned a ROCE of 24% in FY26. Its return on capital used (ROIC) is 12.0 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 22.1% net margin and 0.64× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 22.1% net margin × 0.64× asset turnover × 1.20× leverage (assets divided by equity) ≈ 17.0% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 24.0% − 12.0% = +12.0 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. The 24.0% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 22.0%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Alivus Life Sciences have too much debt? Alivus Life Sciences Ltd has total debt of ₹53.0 Cr against shareholder equity of ₹3,632 Cr as of Sep 2026, so its debt is 0.01× its equity, which is very little. Year by year, that ratio went from 0.00 in FY22 to 0.02 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Alivus Life Sciences shareholding pattern? Domestic institutions raised their stake in Alivus Life Sciences Ltd by 2.9 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 7.0% of the company. Foreign institutions moved −1.9 points over the same period, to 5.9%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: +2.9 points over 8 quarters, to 7.0%; Foreign institutions: −1.9 points over 8 quarters, to 5.9%; Promoters: −0.2 points over 8 quarters, to 74.8%. Why the owners changed: foreign institutions moved −1.9 points and domestic institutions +2.9 points over 8 quarters, while promoters stayed about the same. One group of institutions took over shares from the other; it is not a change of mind by the people running the company. ## How far is Alivus Life Sciences from balance-sheet trouble? For Alivus Life Sciences Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Alivus Life Sciences rank in its industry? 63.5 out of 100, rank 2 of 4 in Pharmaceuticals Bulk Drugs & Formulation, with 97% of the evidence available. Alivus Life Sciences Ltd scores 63.5 out of 100 against the 4 companies it is compared with in Pharmaceuticals Bulk Drugs & Formulation, ranking 2. Earnings are strong; relative strength in its sector is -14.2% and the one-year return is 59%. The four parts add up to the total exactly: 25.7 + 23 + 9.8 + 5 = 63.5. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Alivus Life Sciences compared with? Alivus Life Sciences ranks 2 of 4 Pharmaceuticals Bulk Drugs & Formulation companies on the 4-Factor Sector Score, with 63.5 out of 100. 1. [Anlon Healthcare Ltd](https://www.sectoralpha.in/stocks/anlon-healthcare-ltd) AHCL · breaking out · Most evidence points up · 74% evidence 65.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.3/35 · Revenue 26.9% · Profit 2.8% · Operating margin change -2.3 points · 100% evidence Capital efficiency 19.2/25 · ROCE 22.4% (year to Mar 2026) · Operating margin 23.9% · 100% evidence Valuation 10.0/20 · P/E 48.4× · PEG n/a · 0% evidence Relative strength 17.0/20 · Strength vs its industry (price vs its 52-week average, weekly) 9% · Strength vs NIFTY 500 (same reading) 57.6% · 1 year 62.3% · 70% evidence · 12 of 12 weeks ahead Exact sum: 19.3 + 19.2 + 10 + 17 = 65.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. Alivus Life Sciences Ltd this page ALIVUS · losing its lead · Evidence leans up · 97% evidence 63.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.7/35 · Revenue 8.1% · Profit 26.2% · Operating margin change 9 points · 100% evidence Capital efficiency 23.0/25 · ROCE 23.8% (year to Mar 2026) · Operating margin 38.9% · 100% evidence Valuation 9.8/20 · P/E 26.3× · PEG 1.41 · 85% evidence Relative strength 5.0/20 · Strength vs its industry (price vs its 52-week average, weekly) -14.2% · Strength vs NIFTY 500 (same reading) 27.5% · 1 year 59% · 100% evidence · 11 of 12 weeks ahead Exact sum: 25.7 + 23 + 9.8 + 5 = 63.5 · What this means: Earnings are strong; relative strength in its sector is -14.2% and the one-year return is 59%. 3. [Valiant Laboratories Ltd](https://www.sectoralpha.in/stocks/valiant-laboratories-ltd) VALIANTLAB · breaking out · Evidence leans up · 65% evidence 60.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 33.3/35 · Revenue 100% · Profit 100% · Operating margin change 4.3 points · 100% evidence Capital efficiency 4.8/25 · ROCE 0.6% (year to Mar 2026) · Operating margin 4.4% · 100% evidence Valuation 10.0/20 · P/E 31.9× · PEG n/a · 0% evidence Relative strength 12.5/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 27.9% · 1 year n/a · 25% evidence · 7 of 7 weeks ahead Exact sum: 33.3 + 4.8 + 10 + 12.5 = 60.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Amanta Healthcare Ltd](https://www.sectoralpha.in/stocks/amanta-healthcare-ltd) AMANTA · leader · Evidence leans up · 74% evidence 60.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.2/35 · Revenue 9.9% · Profit 22.5% · Operating margin change 0 points · 100% evidence Capital efficiency 12.3/25 · ROCE 11.6% (year to Mar 2026) · Operating margin 20.7% · 100% evidence Valuation 10.0/20 · P/E 47.2× · PEG n/a · 0% evidence Relative strength 17.0/20 · Strength vs its industry (price vs its 52-week average, weekly) 9.4% · Strength vs NIFTY 500 (same reading) 59.8% · 1 year 90.6% · 70% evidence · 11 of 12 weeks ahead Exact sum: 21.2 + 12.3 + 10 + 17 = 60.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharmaceuticals Bulk Drugs & Formulation](https://www.sectoralpha.in/sectors/pharmaceuticals-bulk-drugs-formulation), all 4 compared on one page. ## Which companies are close to Alivus Life Sciences in size? Alivus Life Sciences is the largest of 4 Pharmaceuticals Bulk Drugs & Formulation companies on Sector Alpha by market value (at the 20 November 2026 close). It is the largest. Just below it: Anlon Healthcare, Amanta Healthcare and Valiant Laboratories. ### Pharmaceuticals Bulk Drugs & Formulation companies close in size 1. Alivus Life Sciences Ltd ₹17,670 crore 2. [Anlon Healthcare Ltd](https://www.sectoralpha.in/stocks/anlon-healthcare-ltd) ₹1,338 crore 3. [Amanta Healthcare Ltd](https://www.sectoralpha.in/stocks/amanta-healthcare-ltd) ₹863 crore 4. [Valiant Laboratories Ltd](https://www.sectoralpha.in/stocks/valiant-laboratories-ltd) ₹515 crore [All 4 Pharmaceuticals Bulk Drugs & Formulation companies, largest first](https://www.sectoralpha.in/sectors/pharmaceuticals-bulk-drugs-formulation#all-companies) ### Companies close in size in other industries 1. [Lalithaa Jewellery Mart Ltd](https://www.sectoralpha.in/stocks/lalithaa-jewellery-mart-ltd) ₹17,723 crore 2. [Cohance Lifesciences Ltd](https://www.sectoralpha.in/stocks/cohance-lifesciences-ltd) ₹17,689 crore · Pharma - API & CRAMS 3. Alivus Life Sciences Ltd ₹17,670 crore 4. [Elgi Equipments Ltd](https://www.sectoralpha.in/stocks/elgi-equipments-ltd) ₹17,648 crore · Compressors 5. [Pfizer Ltd](https://www.sectoralpha.in/stocks/pfizer-ltd) ₹17,640 crore · Pharma - MNC bulk Drugs ## What else do people ask about Alivus Life Sciences? ### What is Alivus Life Sciences's share price today? Alivus Life Sciences Ltd's share price is ₹1,436.90, +59.0% over the past year. The whole company is worth ₹17,665 Cr on the market. In the last 52 weeks it traded between ₹880 to ₹1,559; today it is 82% of the way up from the low, 19.0% above its 200-day average (as of 20 November 2026). ### What were Alivus Life Sciences's latest quarterly results? Alivus Life Sciences Ltd reported revenue of ₹682 Cr and net profit of ₹197 Cr for the Sep 2026 quarter. Revenue rose 16.0% and profit rose 51.5% compared with a year earlier. Earnings per share were ₹16.03. The operating margin was 38.9%, 8.5 percentage points higher than a year earlier (as of 20 November 2026). ### What is Alivus Life Sciences's market cap? Alivus Life Sciences Ltd's market capitalisation is ₹17,665 Cr at a share price of ₹1,436.90. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 20 November 2026). ### How is Alivus Life Sciences performing? Alivus Life Sciences Ltd's share price has been rising for 31 weeks. In its latest quarter, revenue rose 16.0% and profit rose 51.5% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 26 weeks running (as of 20 November 2026). ### Will Alivus Life Sciences's share price go up? This page does not forecast Alivus Life Sciences Ltd's share price. What it shows instead: the share price is ₹1,436.90, and it has been rising for 31 weeks. Its P/E of 26.3× is higher than 81% of its own last 5 years (as of 20 November 2026). ### Who owns Alivus Life Sciences? Promoters own 74.8% of Alivus Life Sciences Ltd, foreign institutions 5.9%, domestic institutions 7.0% and the public 12.2% (latest quarter). The biggest change over the last two years: Domestic institutions raised their stake by 2.9 percentage points over 8 quarters (as of 20 November 2026). ### Does Alivus Life Sciences have too much debt? No, Alivus Life Sciences Ltd has little debt: its debt is 0.02× its equity, and its operating profit is more than 100 times its interest bill. FY26 borrowings were ₹57.0 Cr against equity of ₹3,333 Cr. So the returns on this page come from the business, not borrowed money (as of 20 November 2026). ### Where is Alivus Life Sciences in its business cycle? Alivus Life Sciences Ltd's FY26 operating margin was 31.3%, against a 9-year range of −4.0% to 31.4%. The latest quarter was 38.9%, above the top of its own yearly range in the latest quarter, so margins are at a high and the story depends on them staying there. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 20 November 2026). ### What could break the Alivus Life Sciences story? The main question: the share price moved +59.0% in a year while yearly earnings per share moved +16.0%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 20 November 2026). ### Is Alivus Life Sciences a stock worth studying right now? What the numbers show: Alivus Life Sciences Ltd's share price has risen faster than its earnings: +59.0% in a year, against +16.0% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 20 November 2026). ### Is there a Alivus Life Sciences share price forecast for 2026? What management itself guided: FY27 revenue growth 10-12% reiterated on H2 strength and launch traction. ### Where does this page get Alivus Life Sciences' management information? From Alivus Life Sciences' results calls, its filings and public records on governance, each dated on the page. Management’s plans are shown as plans, never as results. ## Lists - Multibagger study list: https://www.sectoralpha.in/multibagger-stocks-india - Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india - Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india - Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india This is research, not advice. We’re not SEBI-registered.